A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

NCT01050998 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

516

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: Mavrilimumab 10 mg
BIOLOGICAL: Mavrilimumab 30 mg
BIOLOGICAL: Mavrilimumab 50 mg
BIOLOGICAL: Mavrilimumab 100 mg
OTHER: Placebo

Sponsor

MedImmune LLC

Collaborators

[object Object]